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Despite reports of the successful isolation of primary equine hepatocytes, there
are no published data regarding the successful cryopreservation of these isolated
cells. In this study, a detailed description of the procedures for isolation, cryop-
reservation, and recovery of equine hepatocytes are presented. Furthermore, the
intrinsic clearance (Clint) and production of metabolites for three drugs were
compared between freshly isolated and recovered cryopreserved hepatocytes. Pri-
mary equine hepatocytes were isolated using a two-step collagenase perfusion
method, with an average cell yield of 2.47  2.62 9 106 cells/g of perfused liver
tissue and viability of 84.1  2.62%. These cells were cryopreserved with Wil-
liam’s medium E containing 10% fetal bovine serum with 10% DMSO. The via-
bility of recovered cells, after a 30% Percoll gradient, was 77  11% and
estimated recovery rate was approximately 27%. These purified cells were used
to determine the in vitro Clint of three drugs used in equine medicine; omepra-
zole, flunixin, and phenylbutazone, via the substrate depletion method. Cryopre-
served suspensions gave a comparable estimation of Clint compared to fresh cells
for these three drugs as well as producing the same metabolites. This work paves
the way for establishing a bank of cryopreserved equine hepatocytes that can be
used for estimating pharmacokinetic parameters such as the hepatic metabolic
in vivo clearance of a drug as well as producing horse-specific drug metabolites.
Abbreviations
BSA, bovine serum albumin; CLint, intrinsic clearance; DMSO, dimethyl sulfoxide;
EGTA, ethylene glycol tetraacetic acid; EPC, effective plasma drug concentration;
ESI, electrospray ionization; FBS, fetal bovine serum; HBSS, Hanks balanced salt
solution; HPLC, high-performance liquid chromatography; IPC, irrelevant plasma
concentration; MS, mass spectrometer; PD, pharmacodynamics; PK, pharmacoki-
netics; TB, Trypan Blue; WEM, Williams medium E.
Introduction
Horses have both a commercial and a domestic role within
society, ranging from companion animals to the equine
sports and food industries. In all cases, the welfare of the
horses must be considered, including appropriate medica-
tion when necessary. The optimal dosing regimen for a med-
ication is dependent on a thorough understanding of the
drug pharmacokinetics (PK). The clearance of a drug is par-
ticularly important, especially when determining the average
concentration of a drug once steady-state has been reached.
The equine sports industry is a multi-billion dollar
industry (British Horseracing Authority, 2013) and, while
medication is allowed when the horse is in training, most
international equine sports jurisdictions’ require the horse
to be free of medication on the day of the competition.
Therefore, where a horse competes having received medi-
cation in its training program, the term “free of any med-
ication” has to be defined. One such definition can be a
drug concentration in plasma that is less than the concen-
tration required for a significant therapeutic effect. Tou-
tain and Lassourd (2002) proposed an approach based
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upon the above definition that also takes into account
variation in both PK and pharmacodynamic (PD) param-
eters for a population of horses. An estimate of the irrele-
vant plasma concentration (IPC) is based upon a
pharmacologically effective plasma drug concentration
(EPC) divided by an appropriate safety factor. The EPC is
the average concentration at steady-state and is estimated
from the therapeutic dose, dosing interval, and clearance
of the drug. The IPC can be used for deriving a drug
screening limit, which in turn can be used in conjunction
with drug in vivo PK profiles to obtain appropriate drug
withdrawal times.
In vivo PK studies including bioanalysis are expensive as
well as involving invasive sampling from the animal. It is
now standard practice within the pharmaceutical industry
to use in vitro tissue models to estimate the clearance of a
drug in human and reduce the number of preclinical ani-
mals used. The use of primary hepatocytes has been prac-
ticed for more than five decades (Berry and Edwards 2001).
Primary hepatocytes are considered as a “gold standard”
for evaluating hepatic metabolism and toxicity of drugs
and other xenobiotics in vitro and potential drug-drug
interactions (Dambach et al. 2005; Hewitt et al. 2007; Li
2007). Although freshly isolated hepatocytes have a limited
viability in suspension of up to 4 h, this period is long
enough to determine the metabolic stability of a drug and
to allow identification of major metabolites (Jouin et al.
2006; Soldatow et al. 2013). The limited availability of fresh
cells restrains their use, however, cryopreservation offers an
option for long-term storage of hepatocytes providing a
continuous and sufficient “off the shelf” supply (Bachmann
et al. 2003; Griffin and Houston 2004; Terry et al. 2010).
Fresh equine primary hepatocytes have successfully
been isolated and cultured (Bakala et al. 2003; Stefanski
et al. 2013). However, there is no literature evidence
describing the cryopreservation and recovery of equine
hepatocytes and the resulting cell viability and activity of
xenobiotic metabolizing enzymes. A better understanding
of equine drug metabolism is important for optimal
administration regimens of drugs and the resulting effects
of the applied treatment. As a consequence, equine veteri-
nary surgeons will be better informed with regard to the
outcomes of administered drugs and as a result potential
drug-drug interactions may be avoided. This will ulti-
mately lead to improved welfare of the horse population.
Furthermore, a greater understanding of how drugs are
metabolized in the horse, including rates of metabolism
and metabolites generated using in vitro systems, will aid
the equine sports industry regulate for the abuse of medi-
cations and doping substances with a reduction in animal
usage and overall costs.
The aim of this work was to develop and optimize a pro-
tocol for the cryopreservation of equine hepatocytes that can
be recovered with good cell viability and metabolic activity
for use in metabolism studies of the commonly used equine
drugs omeprazole, flunixin, and phenylbutazone.
Materials and Methods
Materials
Collagenase and Calcium-free Hanks Balanced Salt Solu-
tion (HBSS) 910, HEPES buffer, William’s medium E,
and fetal bovine serum (FBS) were purchased from
Thermo Fisher Scientific (Paisley, UK). Dimethyl sulfox-
ide, Percoll, flunixin, ketoprofen, phenylbutazone, diclofe-
nac, and trypan blue were purchased from Sigma (Dorset,
UK). Omeprazole and lanzaprozole were purchased from
Tocris Bioscience (Bristol, UK). All other chemicals were
of reagent grade.
Liver samples
Livers were obtained from seven horses post slaughter (2–
22 years old, of both sexes). The horses were slaughtered
in accordance with the Welfare of Animals at the Time of
Killing (UK) Regulations 2015. Liver lobes (preferably the
left lateral, caudal, or quadrats segment) were excised by
a single transverse cut and immediately after excising
immersed in HBSS (0–2°C) prior to being transported to
the laboratory.
Hepatocyte preparation
For hepatocytes preparation, a “two-step” perfusion pro-
cedure (chelating and collagenase perfusion) was used
based upon Selgens’ method (Selgen 1976). Once in the
laboratory, part of the liver lobe was excised to obtain on
the cutting surface no more than two big hepatic vessels
(5–8 mm in diameter). The resulting lobe segment (90–
110 g) was cannulated and initially perfused with cal-
cium-free Hanks-HEPES solution (44 mL/min/cannula)
until all blood was removed and an outlet temperature of
37°C achieved (8–12 min). The liver segment was then
perfused with Ca2+-free HBSS supplemented with
0.1 mmol/L EGTA (Chelating step) for 10 min, without
recirculation of the perfusate. This was followed by HBSS
buffer (0.5 L) containing 5 mmol/L calcium chloride fol-
lowed immediately by recirculating HBSS buffer contain-
ing 5 mmol/L calcium chloride and collagenase (0.1% w/
v), through the liver segment for 15–25 min at the same
flow rate. All perfusion buffers were prewarmed to 40°C
with the exception of the collagenase solution which was
prewarmed to 37°C. The digested liver segment was then
transferred to a 10 cm Petri dish and disrupted gently,
using pointed scissors to tear the liver capsule.
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Purification of the initial cell suspension
The digested liver tissue was dispersed in 100 mL HBSS
buffer containing 0.1% w/v albumin at 4°C. The resulting
cell suspension was twice filtered, first through a 250 lm
nylon mesh followed by a 100 lm nylon mesh. Next,
HBSS buffer containing albumin was added to the filtered
suspension to reach a final volume of 300 mL. Once
resuspended, the cell suspension was centrifuged for
5 min at 75g followed by 3 min at 50g. Cell pellets were
resuspended in 45 mL HBSS buffer containing albumin
and placed on ice.
Determination of hepatocytes yield and
viability
The yield and viability of freshly isolated hepatocytes were
assessed with Trypan Blue (TB) dye exclusion test (Ten-
nant 1964). A quantity of 15 lL TB was mixed with the
same volume of cell suspension and stained (nonviable)
and unstained (viable) cells were counted in a hemocy-
tometer. Viability % was determined from the percentage
of live cells to total cell count.
Cryopreservation of freshly isolated
hepatocytes
Hepatocytes were cryopreserved according to a modified
protocol by Adams et al. (1995): The main modification
was use of 50% v/v Williams E medium, 40% v/v Fetal
calf serum, and 10% v/v DMSO as cryopreservation
media. Cells were pelleted at 50g for 3 min at 4°C, the
supernatant was removed by aspiration, and the pellet
was resuspended in cryopreservation media prepared fresh
at the time of cryopreservation under sterile conditions.
The cryopreservation medium was added dropwise while
the suspension was gently shaken. After resuspension, the
cells were placed on ice and aliquoted (1 mL of cell sus-
pension/cryovial at a concentration of 1 9 107 cells/mL).
The vials were then transferred into Mr Frosty iso-
propanol Containers (Fisher, UK) and cooled at a rate of
1°C/min in a 80°C Freezer. After 18 h, the vials were
transferred to liquid nitrogen for long-term storage at
196°C.
Cell recovery
Cryopreserved equine hepatocytes were recovered by
thawing the vials in a 37°C water bath under gentle agita-
tion. The cells were diluted 1:10 by drop wise addition of
prewarmed WEM plus 10% fetal bovine serum as previ-
ously described by Terry et al. 2010. Cells were pelleted at
50g for 5 min at room temperature and suspended in
prewarmed WEM. Hepatocyte yield and viability was
determined immediately post-thaw by TB exclusion.
Recovery of cryopreserved hepatocytes for
drug clearance assays
After thawing, viable cells were purified using two differ-
ent Percoll gradients (25 and 30%). A quantity of 15 mL
of the Percoll solution was overlaid with the content of
one vial and centrifuged at 110g at 4°C for 20 min (Krea-
mer et al. 1986; SciKon Innovation 2010). After centrifu-
gation, the dead cells and the cell debris were located at
the interface while viable cells were pelleted. The pelleted
cells were resuspended in WEM and washed by centrifu-
gation for 3 min at 50g.
Determination of intrinsic clearance
Freshly isolated or recovered cryopreserved hepatocytes
were diluted to 1 million cells/mL, using WEM with
0.125% v/v bovine serum albumin (BSA), and were prein-
cubated for 30 min at 37°C with 5% CO2 as previously
described by Jouin et al. (2006). All incubations were per-
formed in 1.2 mL cluster tubes (Sigma, Dorset, UK) in a
96-well heater block (BioShake iQ), set at 750 rpm and
37°C with a total incubation volume of 1 mL. Drug
stocks were prepared in DMSO at 1009 final incubation
concentration (5 lmol/L). The reaction was initiated by
adding 10 lL of each drug stock to cell suspension. Then,
100 lL aliquots were removed at 0, 5, 10, 20, and 30 min
and quenched in 200 lL of ice-cold methanol containing
internal standard (10 lmol/L). Samples were subsequently
frozen at 20°C until further analysis. Samples were cen-
trifuged at 31g for 10 min at 4°C prior to HPLC analysis.
The supernatant was removed and transferred into HPLC
vials and analyzed.
LC/MS analysis
Peak area ratios of omeprazole, flunixin, and phenylbuta-
zone to their respective internal standard (lansoprazole,
ketoprofen, and diclofenac) were determined using high-
performance liquid chromatography (Agilent 1100 HPLC
Palo Alto, CA) and mass spectrometer detector (Quattro
ultima VB250) HPLC/MS system. Separation was per-
formed on a C18 column (Discovery, 5 lm particle size,
15 cm 9 3.0 mm) (Sigma, UK). The mobile phase con-
sisted of Solvent A (10% methanol, 90% water, and
0.02% formic acid) and Solvent B (100% methanol con-
taining 0.02% formic acid). The solvent flow rate was
kept at a constant 0.5 mL/min with an upper pressure
limit of 400 bar. All compounds were detected by positive
electrospray ionization (ESI) in the selected ion
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monitoring mode using predetermined parent MH/Z and
oxidative metabolites MH+16/Z. The intrinsic clearance
was determined using the drug substrate depletion
approach where the slope of the logarithm of MS parent
drug response versus time was determined and converted
into appropriate units.
Statistical analysis
The data are presented as mean of seven cell preparations
standard deviations. Statistical significance was esti-
mated by the paired, two-tailed Student’s test. A P < 0.05
was considered significant.
Results and Discussion
Yield and viability of fresh and
cryopreserved equine hepatocytes
The average of total yielded viable fresh hepatocytes was
249  198 9 106 cells per isolation, which equated to
4.36  2.47 9 106 cells per gram of perfused tissue.
Hepatocyte viability was on average 84.1  2.62%
(Table 1) and is comparable to that reported by Bakala
et al. (2003) of 82.7  10.2% and Stefanski et al. (2013)
of 84.6  6.4%. However, the number of hepatocytes iso-
lated per gram of perfused tissue was fivefold higher than
that reported by Stefanski et al. (2013) (n = 9) but five-
fold lower than in the study by Bakala et al. (2003).
Although protocols were similar, Bakala et al. (2003) used
a University of Wisconsin proprietary solution for trans-
portation, which may have superior organ preservation
capacities, enabling a larger viable cell yield to be
obtained. Another potential factor is the number of liver
samples, which was greater (n = 264) .
Cryopreserved equine hepatocytes had a post-thaw via-
bility of 60.3  12% (Table 2). The results obtained in
this study were consistent with data obtained from other
species such as rats and human. For rat cryopreserved
hepatocytes, the immediate post-thaw viability of 60%
was achieved by Sosef et al. (2005). Meanwhile, Terry
et al. (2010) obtained post-thaw viability of 52  9%
using cryopreserved human hepatocytes. A batch of cry-
opreserved equine hepatocytes were stored for up to
16 months in liquid nitrogen and no effect on post-thaw
viability was observed in that time frame (Fig. 1). Two
concentrations of Percoll gradient (25% and 30%) were
used in this study to examine their effect on the percent-
age viability and recovery. A 25% Percoll treatment
increased hepatocyte viability from 52  14 to
62.3  11% with 31.6  6% recovery (n = 3). However,
the average viability after 30% Percoll treatment was
77  11% with an average recovery of 27  7%













1 19 100 4.10 87.7
2 18 90 9.33 83.0
3 3 100 3.83 81.0
4 6 90 4.88 83.7
5 18 80 1.6 82.6
6 14 80 2.4 87.7
7 25 80 4.4 82.7
Mean 4.36 84.1
SD 2.47 2.62
Table 2. Post-thaw viability with and without 30% Percoll gradient














1 61.1 75.0 2.80
2 35.0 53.5 3.44
3 59.0 76.2 1.22
4 71.0 87.7 2.56
5 62.7 81.3 3.20
6 65.3 83.3 3.33
7 69.1 82.1 2.31
Mean 60.5 77.0 2.69
SD 12.0 11.0 0.8


















Figure 1. Effect of storage time on equine hepatocyte post-thaw
viability. Cryopreserved hepatocytes were stored in liquid nitrogen
from 2 to 480 days. The results show that long storage of equine
hepatocytes in liquid nitrogen has no effect on cell viability.
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(Table 2). The recovery percentage was higher with 25%
Percoll and is consistent with results reported by McGin-
nity et al. (2004). However, the post-thaw viability after
25% Percoll reported herein was lower than the accept-
able limit for enzyme kinetic studies. In their study,
McGinnity et al. (2004), found that a 25% Percoll treat-
ment increased dog and human hepatocyte viability from
52  1 to 78  8% and 66  2 to 88  3%, respec-
tively. Therefore, a 30% Percoll concentration was used
for kinetic studies since it gave a higher post-thaw viabil-
ity with an acceptable recovery. The Percoll density gradi-
ent has often been used for cell separation and to increase
viability by separating live from dead cells (Kreamer et al.
1986; Innes et al. 1988; Diener et al. 1993). Moreover,
several studies have found that the use of this gradient
has an advantage for cell function, including cytochrome
P450 function and cell attachment (Dou et al. 1992;
Utesch et al. 1992; McGinnity et al. 2004).
The present work uses simple conventional commer-
cially available solutions and tissue culture materials and
methods for isolation and cryopreservation of equine hep-
atocytes with no need for specialized equipment or tech-
niques and appears very effective. However, further
optimization of the described methods may lead to an
increased number of hepatocytes isolated per gram of
perfused tissue and improvement of post-thaw cell viabil-
ity and function.
Comparison of intrinsic clearance and
metabolite formation between fresh and
cryopreserved equine hepatocytes
This work also investigated the effect of cryopreservation
on xenobiotic metabolizing enzymes. Intrinsic clearance is
used as an indicator for the efficiency of metabolism and
can be scaled to in vivo plasma clearance with knowledge
of physiological parameters such as microsomal protein
content, hepatocellularity, liver weight, and a model of
hepatic extraction such as the well-stirred model (Hous-
ton 1994; Naritomi et al. 2001). Intrinsic clearances for
omeprazole, flunixin, and phenylbutazone were deter-
mined by the substrate depletion method. These drugs
were chosen because they are known to produce metabo-
lites from in vivo studies (Neto et al. 1996; Kanazawa
et al. 2002; Jedziniak and Szprengier-juszkiewicz 2005;
Jedziniak et al. 2007). The results of this study show that
there is no significant difference (P > 0.5) in intrinsic
clearance between fresh and cryopreserved hepatocytes for
the drugs investigated (Fig. 2). The mean  SD (n = 3)
of Clint for omeprazole, flunixin, and phenylbutazone
were 21.3  6.7, 16.3  0.5, 19  6.2, and 18.7  4,
24  12.49 and 16.7  5.5 in fresh and cryopreserved
hepatocytes, respectively.
Moreover, Figure 3 shows the mass chromatograms of
oxidation metabolites (MH+16/Z) generated for omepra-
zole in fresh (A and B) and cryopreserved (C and D) equine
hepatocytes. Metabolites of omeprazole were characterized
by comparison of the negative control chromatogram (0
time point, Fig. 3A and C) with the chromatogram of the
30 min time point (Fig. 3B and D). Oxidation metabolite
peaks are presented by M1, M2, and M3 with retention
times (RT) 4.22, 4.96, and 5.57 min. This suggests that M1
and M2 are more polar than omeprazole, whereas M3 is
less. Kanazawa et al. (2002) determined a RT order of 5-
hydroxyomeprazole, omeprazole, and then omeprazole sul-
fone suggesting either M1 or M2 is 5-hydroxyomeprazole
and M3 is omeprazole sulfone. This study also identified 3-
hydroxyomeprazole as a minor metabolite, and although
no RT has been published, it is a reasonable assumption
that either M1 or M2 is 3-hydroxyomeprazole. The ratio
between peak areas of M1, M2, and M3 was 2:1:1, respec-
tively, in both fresh and cryopreserved hepatocytes (Fig. 3A
and B). A phenylbutazone oxidation metabolite was char-
acterized by comparison of the negative control
Figure 2. Comparison of intrinsic clearance between fresh and cryopreserved hepatocytes (mean presented by dash line) for omeprazole (A),
flunixin (B), and phenylbutazone (C) (n = 3 horses for each drug). The results show that there is no significant difference between fresh and
cryopreserved equine hepatocytes, P > 0.5.
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chromatogram (0 time point, Fig. 4A and C) with the
chromatogram of the 30 min time point (Fig. 4B and D).
This metabolite was identified as oxyphenbutazone since it
showed an identical retention time to an authentic
oxyphenbutazone standard. Oxyphenbutazone was
detected for both fresh and cryopreserved hepatocytes,
however, the intensity, after normalizing for internal stan-
dard, was 50% lower for the latter which may suggest some
degradation in the metabolizing enzyme. No significant
oxidation metabolites were observed for flunixin which is
known to mainly undergo phase II metabolism in camel
(Wasfi et al. 1998). Selected ion monitoring for glu-
curonide metabolites (MH+176/Z) showed no detectable
metabolites. The observations observed in this study with
equine hepatocytes are consistent with the literature for
other species (Diener et al. 1993; McGinnity et al. 2004).
Moreover, Griffin and Houston (2004) found that cryopre-
served human hepatocytes gave similar high clearances for
propranolol and diazepam compared to fresh hepatocytes.
In conclusion, this study has shown that equine hepa-
tocytes can be successfully cryopreserved using a conven-
tional freezing protocol. The use of a Percoll
centrifugation after thawing yielded equine hepatocytes
with high viability, which appear to possess an enzymatic
metabolic capability similar to that of freshly isolated
hepatocytes. A continuous availability of cryopreserved
equine hepatocytes represents a major advantage as a tool
for drug screening in the horse.
Figure 3. High-performance liquid chromatography-mass spectrometer (HPLC-MS) chromatograms of oxidation metabolites of Omeprazole in
suspension cultures of fresh (A = 0 min and B = 30 min) and recovered cryopreserved (C = 0 min and D = 30 min) equine hepatocytes. The ratio
between the peak areas of M1, M2, and M3 was 2:1:1, respectively, in both fresh and cryopreserved hepatocytes.
Figure 4. High-performance liquid chromatography-mass spectrometer (HPLC-MS) chromatogram of oxidation metabolites of phenylbutazone in
suspension cultures of fresh (A = 0 min and B = 30 min) and recovered cryopreserved (C = 0 min and D = 30 min) equine hepatocytes.
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